Geneva, Switzerland

Elie Dheilly

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2023

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Elie Dheilly: Innovator in Monoclonal Antibodies

Introduction

Elie Dheilly is a prominent inventor based in Geneva, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of two patents to his name, Dheilly's work focuses on innovative therapeutic solutions.

Latest Patents

Elie Dheilly's latest patents include groundbreaking inventions related to anti-CD47 and anti-CD19 antibodies. These inventions involve monoclonal and/or monovalent antibodies that specifically bind to CD47 and CD19. Additionally, he has developed novel bispecific monoclonal antibodies that possess different specificities for each binding site of the immunoglobulin molecule. One of these binding sites is specific for CD47, while the other is specific for CD19. These advancements hold promise for enhancing therapeutic efficacy in various medical applications.

Career Highlights

Dheilly is currently associated with Novimmune SA, a company known for its focus on developing innovative antibody-based therapies. His work at Novimmune has positioned him as a key player in the biotechnology sector, contributing to the advancement of medical treatments through his inventions.

Collaborations

Elie Dheilly collaborates with notable colleagues, including Krzysztof Masternak and Nicolas Fischer. These partnerships enhance the research and development efforts within the company, fostering an environment of innovation and creativity.

Conclusion

Elie Dheilly's contributions to the field of monoclonal antibodies exemplify the impact of innovative thinking in biotechnology. His patents and work at Novimmune reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…